Full-Time

Area Business Specialist

Endocrinology, Rare Disease

Posted on 12/3/2025

Deadline 1/26/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$110k - $190k/yr

+ Commission + Equity

Salt Lake City, UT, USA

Remote

Remote role with ~70% travel; occasional on-site requirements in Salt Lake City, UT.

Category
Sales & Account Management (1)
Requirements
  • BA/BS required
  • 5-7+ years of successful pharmaceutical sales experience required
  • A valid, US State-issued driver’s license is required
Responsibilities
  • Effectively promote and educate specialty physicians on the appropriate use of rare disease products through one-on-one meetings and group presentations, company-approved promotional speaker programs and other company-approved means.
  • Responsible for achieving both territory product sales goals and territory sales activity goals through company defined metrics.
  • Ensure high performance levels of call and field productivity. Meet territory product sales goals while adhering to all defined ethical sales practices, compliance guidelines and required promotional regulations
  • Execute company-approved Product Marketing plans and territory/regional business plan activities
  • Support targeted customers and accounts using company-approved resources, sales materials and promotional activities/programs/initiatives as identified by Sales Leadership
  • Appropriately managing/maintaining all company equipment and company-approved promotional materials (e.g., sales materials, company literature, product samples, etc.) according to defined company compliance guidelines
  • Ensure optimum territory sales strategy execution using territory business plans, regional business plans and all appropriate sales reports
  • Communicate cross-functionally to gather knowledge of best practices from peers within the organization.
  • Attend all company-sponsored sales and medical related meetings as directed by company management.
  • Actively pursue continuous learning and professional sales development on effective sales/communication techniques and product/therapeutic area knowledge
Desired Qualifications
  • 2+ years of experience promoting rare competitive disease products strongly preferred
  • Launch experience or start-up experience is a plus
  • Experience working with Endocrinologists preferred
  • Deep understanding of all stakeholders in an office and ability to support them in getting a patient started on therapy within guardrails established by the company
  • Demonstrated ability to both build relationships within existing accounts as well as proactively find new accounts
  • Previous experience working with specialty pharmacies and internal patient support roles preferred
  • Experience navigating managed care and rare disease products preferred
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $49.8 million in Q1 2026.
  • Xeris raised 2026 revenue guidance to $380 million-$390 million after strong Q1.
  • XP-8121 remains on track for Phase 3 initiation later in 2026.

What critics are saying

  • Gvoke faces Medicare coverage pressure, keeping revenue flat at $20.8 million.
  • Recorlev faces generic litigation threats from two applicants targeting March 2040 patents.
  • XP-8121 remains pre-Phase 3, leaving Xeris dependent on current marketed products.

What makes Xeris Pharmaceuticals unique

  • Xeris builds ready-to-use liquid-stable injectables through XeriSol and XeriJect.
  • Gvoke replaces multi-step glucagon mixing with pre-filled syringe and auto-injector options.
  • Recorlev and Keveyis target rare endocrine and neuromuscular diseases with limited competition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xeris Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

2%
Living Vision International Ministries
May 7th, 2026
Xeris Biopharma: Q1 earnings snapshot.

Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

INACTIVE